Ira Winer, MD, PhD, associate professor, Division of Gynecologic Oncology, Wayne State University, Barbara Ann Karmanos Cancer Institute, discusses the tolerability of ALKS 4230 plus pembrolizumab (Keytruda) in ovarian cancer. 

Findings from the ongoing phase 1/2 ARTISTRY-1 trial were presented during the 

The results demonstrated objective responses with the combination of ALKS 4230, an investigational engineered cytokine, and pembrolizumab in patients with heavily pretreated, platinum-resistant ovarian cancer. 

The ARTISTRY-1 regimen is intensive, but patients appeared to tolerate the combination well, says Winer. 

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Ovarian Cancer

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Society for Immunotherapy of Cancer

Oncology Societies

Partner

Ira Winer, MD, PhD, discusses the tolerability of ALKS 4230 plus pembrolizumab in ovarian cancer. 

Dr. Winer on the Tolerability of ALKS 4230 Plus Pembrolizumab in Ovarian Cancer